Real world data in the era of Immune Checkpoint Inhibitors (ICIs): increasing evidence and future applications in lung cancer

During the course of last five years, the introduction of a new class of drugs, the immune checkpoint inhibitors (ICIs), has dramatically changed the treatment of lung cancer. Anti-PD1 (pembrolizumab and nivolumab) and anti-PD-L1 (atezolizumab and durvalumab) are able to avoid certain tumor immune-escaping mechanisms, thus restoring the antitumor response of patient ’s immune system[1]. ICIs were firstly introduced as first or second line treatment of patients with advanced stage disease, both in PD-L1 selected (pembrolizumab) and all comers[2–5]; later on, durvalumab was introduced as consolidation treatment in the algorithm of PD-L1 positive locally-advan ced non-small cell lung cancer NSCLC[6].

Source: Cancer Treatment Reviews - May 14, 2020 Category: Cancer & Oncology Authors: Giulia Pasello, Alberto Pavan, Ilaria Attili, Alberto Bortolami, Laura Bonanno, Jessica Menis, PierFranco Conte, Valentina Guarneri Tags: Hot Topic Source Type: research